Remdesivir potently inhibits carboxylesterase-2 through covalent modifications: signifying strong drug-drug interactions.
Fundam Clin Pharmacol
; 35(2): 432-434, 2021 Apr.
Article
in English
| MEDLINE | ID: covidwho-998909
ABSTRACT
Remdesivir was recently approved to treat COVID-19. While this antiviral agent delivers clinical benefits, several safety concerns in many cases have been raised. This study reports that remdesivir at nanomolar concentrations inhibits carboxylesterase-2 (CES2) through covalent modifications. CES2 is a major drug-metabolizing enzyme. The combination of high potency with irreversible inhibition concludes that cautions must be exercised when remdesivir is used along with drugs hydrolyzed by CES2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Adenosine Monophosphate
/
Carboxylesterase
/
Alanine
/
Enzyme Inhibitors
Type of study:
Prognostic study
Limits:
Humans
Language:
English
Journal:
Fundam Clin Pharmacol
Journal subject:
Pharmacology
Year:
2021
Document Type:
Article
Affiliation country:
Fcp.12643
Similar
MEDLINE
...
LILACS
LIS